Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ-50 is the product code for Keigairengyoto, a traditional Japanese Kampo medicine developed and manufactured by Tsumura & Co. It is a complex herbal formulation composed of 17 crude drugs, including Schizonepeta Spike, Forsythia Fruit, and Scutellaria Root. Keigairengyoto is approved in Japan as an ethical pharmaceutical for the treatment of chronic sinusitis, chronic tonsillitis, and acne vulgaris. It is traditionally indicated for individuals with a specific constitutional type characterized by a tendency toward inflammatory conditions of the skin and mucous membranes. The formulation is thought to exert therapeutic effects through a combination of anti-inflammatory, antimicrobial, and immunomodulatory activities. Clinical research, including the jRCTs031180048 trial, has evaluated its efficacy as an adjunctive therapy following endoscopic sinus surgery to improve postoperative outcomes and quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on keigairengyoto.